Human Transbodies to Reverse Transcriptase Connection Subdomain of HIV-1 Gag-Pol Polyprotein Reduce Infectiousness of the Virus Progeny

• Main Authors: Watee Seesuay, Siratcha Phanthong, Jaslan Densumite, Kodchakorn Mahasongkram, Nitat Sookrung, Wanpen Chaicumpa
• Format: Article
• Language: English
• Published: MDPI AG 2021-08-01
• Series: Vaccines
• Subjects: human single-chain antibodies (HuscFvs); cell-penetrating antibodies (transbodies); human immunodeficiency virus 1 (HIV-1); reverse transcriptase connection subdomain (RTCD); Gag-Pol polyprotein
• Online Access: https://www.mdpi.com/2076-393X/9/8/893

HIV-1 progeny are released from infected cells as immature particles that are unable to infect new cells. Gag-Pol polyprotein dimerization via the reverse transcriptase connection domain (RTCDs) is pivotal for proper activation of the virus protease (PR protein) in an early event of the progeny virus maturation process. Thus, the RTCD is a potential therapeutic target for a broadly effective anti-HIV agent through impediment of virus maturation. In this study, human single-chain antibodies (HuscFvs) that bound to HIV-1 RTCD were generated using phage display technology. Computerized simulation guided the selection of the transformed <i>Escherichia coli</i>-derived HuscFvs that bound to the RTCD dimer interface. The selected HuscFvs were linked molecularly to human-derived-cell-penetrating peptide (CPP) to make them cell-penetrable (i.e., become transbodies). The CPP-HuscFvs/transbodies produced by a selected transformed <i>E. coli</i> clone were tested for anti-HIV-1 activity. CPP-HuscFvs of transformed <i>E. coli</i> clone 11 (CPP-HuscFv11) that presumptively bound at the RTCD dimer interface effectively reduced reverse transcriptase activity in the newly released virus progeny. Infectiousness of the progeny viruses obtained from CPP-HuscFv11-treated cells were reduced by a similar magnitude to those obtained from protease/reverse transcriptase inhibitor-treated cells, indicating anti-HIV-1 activity of the transbodies. The CPP-HuscFv11/transbodies to HIV-1 RTCD could be an alternative, anti-retroviral agent for long-term HIV-1 treatment.